THE EFFECT OF ARIPIPRAZOLE ON PREPULSE INHIBITION OF THE STARTLE RESPONSE IN NORMAL AND HYPERDOPAMINERGIC STATES IN RATS

REFERENCES

• Bakshi V. P., Geyer M. A. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. Journal of Neuroscience 1998; 18(20)8394–8401
   PubMedGoogle Scholar
• Benkert O., Muller-Siecheneder F., Wetzel H. Dopamine agonists in schizophrenia: A review. European Neuropsychopharmacology 1995; 5(Suppl)43–53
   PubMedGoogle Scholar
• Bowles T. M., Levin G. M. Aripiprazole: A new atypical antipsychotic drug. Annals Pharmacotherapy 2003; 37(5)687–694
   PubMed Web of Science ®Google Scholar
• Braff D., Stone C., Callaway E., Geyer M., Glick I., Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978; 15(4)339–343
   PubMed Web of Science ®Google Scholar
• Braff D. L., Geyer M. A. Sensorimotor gating and schizophrenia. Human and animal model studies. Archives of General Psychiatry 1990; 47(2)181–188
   PubMed Web of Science ®Google Scholar
• Braff D. L., Swerdlow N. R., Geyer M. A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. American Journal of Psychiatry 1999; 156(4)596–602
   PubMed Web of Science ®Google Scholar
• Burris K. D., Molski T. F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F. D., Molinoff P. B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics 2002; 302(1)381–389
   PubMed Web of Science ®Google Scholar
• Cadenhead K. S., Geyer M. A., Braff D. L. Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder. American Journal of Psychiatry 1993; 150(12)1862–1867
   PubMedGoogle Scholar
• Cadenhead K. S., Swerdlow N. R., Shafer K. M., Diaz M., Braff D. L. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: Evidence of inhibitory deficits. American Journal of Psychiatry 2000; 157(10)1660–1668
   PubMed Web of Science ®Google Scholar
• Clark D., Hjorth S., Carlsson A. Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. Journal of Neural Transmission 1985; 62(3–4)171–207
   PubMedGoogle Scholar
• Cornblatt B., Kern R. S., Carson W. H., Ali M. W., Luo X., Green M. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. International Journal of Neuropsychopharmacology 2002; 5(Suppl 1)S185
   Google Scholar
• Davis M. Neurochemical modulation of sensory-motor reactivity: Acoustic and tactile startle reflexes. Neuroscience and Biobehavioral Reviews 1980; 4(2)241–263
   PubMedGoogle Scholar
• Dirks A., Groenink L., Westphal K. G., Olivier J. D., Verdouw P. M., Van Der Gugten J., Geyer M. A., Olivier B. Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs. Neuropsychopharmacology 2003; 28(10)1790–1798
   PubMedGoogle Scholar
• Duncan E., Szilagyi S., Schwartz M., Kunzova A., Negi S., Efferen T., Peselow E., Chakravorty S., Stephanides M., Harmon J., Bugarski-Kirola D., Gonzenbach S., Rotrosen J. Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol. Psychiatry Research 2003; 120(1)1–12
   PubMedGoogle Scholar
• Geyer M. A., Krebs-Thomson K., Braff D. L., Swerdlow N. R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berlin) 2001; 156: 2–3; 117–154
   Google Scholar
• Johansson C., Jackson D. M., Zhang J., Svensson L. Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: Effects of antipsychotics and other agents in rats. Pharmacology, Biochemistry, and Behavior 1995; 52(4)649–654
   PubMedGoogle Scholar
• Kane J. M., Carson W. H., Saha A. R., McQuade R. D., Ingenito G. G., Zimbroff D. L., Ali M. W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 2002; 63(9)763–771
   PubMed Web of Science ®Google Scholar
• Kasper S., Lerman M. N., McQuade R. D., Saha A., Carson W. H., Ali M., Archibald D., Ingenito G., Marcus R., Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. International Journal of Neuropsychopharmacology 2003; 6(4)325–337
   PubMed Web of Science ®Google Scholar
• Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., Morita S. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. Journal of Pharmacology and Experimental Therapeutics 1995; 274(1)329–336
   PubMed Web of Science ®Google Scholar
• Lahti A. C., Weiler M. A., Corey P. K., Lahti R. A., Carlsson A., Tamminga C. A. Antipsychotic properties of the partial dopamine agonist (−)-3-(3- hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biological Psychiatry 1998; 43(1)2–11
   PubMed Web of Science ®Google Scholar
• Mackeprang T., Kristiansen K. T., Glenthoj B. Y. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biological Psychiatry 2002; 52(9)863–873
   PubMedGoogle Scholar
• Mansbach R. S., Geyer M. A., Braff D. L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berlin) 1988; 94(4)507–514
   PubMedGoogle Scholar
• Olbrich R., Schanz H. An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. Journal of Neural Transmission. General Section 1991; 84(3)233–236
   PubMedGoogle Scholar
• Pigott T. A., Carson W. H., Saha A. R., Torbeyns A. F., Stock E. G., Ingenito G. G. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study. Journal of Clinical Psychiatry 2003; 64(9)1048–1056
   PubMed Web of Science ®Google Scholar
• Potkin S. G., Saha A. R., Kujawa M. J., Carson W. H., Ali M., Stock E., Stringfellow J., Ingenito G., Marder S. R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 2003; 60(7)681–690
   PubMed Web of Science ®Google Scholar
• Rigdon G. C. Differential effects of apomorphine on prepulse inhibition of acoustic startle reflex in two rat strains. Psychopharmacology (Berlin) 1990; 102(3)419–421
   PubMedGoogle Scholar
• Svensson K., Ekman A., Piercey M. F., Hoffmann W. E., Lum J. T., Carlsson A. Effects of the partial dopamine receptor agonists SDZ 208–911, SDZ 208–912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn-Schmiedeberg's Archives of Pharmacology 1991; 344(3)263–274
   PubMedGoogle Scholar
• Svensson L. The role of the dopaminergic system in the modulation of the acoustic startle response in the rat. European Journal of Pharmacology 1990; 175(1)107–111
   PubMedGoogle Scholar
• Swerdlow N. R., Braff D. L., Geyer M. A., Koob G. F. Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biological Psychiatry 1986; 21(1)23–33
   PubMedGoogle Scholar
• Swerdlow N. R., Geyer M. A., Braff D. L. Neural circuit regulation of prepulse inhibition of startle in the rat: Current knowledge and future challenges. Psychopharmacology (Berlin) 2001; 156: 2–3; 194–215
   Google Scholar
• Swerdlow N. R., Varty G. B., Geyer M. A. Discrepant findings of clozapine effects on prepulse inhibition of startle: Is it the route or the rat?. Neuropsychopharmacology 1998; 18(1)50–56
   PubMedGoogle Scholar
• Tadori Y., Miwa T., Tottori K., Burris K. D., Stark A., Mori T., Kikuchi T. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. European Journal of Pharmacology 2005; 515(1–3)10–19
   PubMed Web of Science ®Google Scholar
• Tamminga C. A. Partial dopamine agonists in the treatment of psychosis. Journal of Neural Transmission 2002; 109(3)411–420
   PubMed Web of Science ®Google Scholar
• Varty G. B., Higgins G. A. Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology (Berlin) 1995; 122(1)15–26
   PubMed Web of Science ®Google Scholar